Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

• Matthew Thompson,
• Laure Lacoin,
• Geoff Hall,
• Michael Snee,
• Sue Cheeseman,
• Majid Riaz,
• Will Sopwith,
• Carlos Chaib,
• John R Penrod,
• Melinda J Daumont

Affiliations

Matthew Thompson

REAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Laure Lacoin

Epi-Fit, Bordeaux, Nouvelle-Aquitaine, UK

Geoff Hall

Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Michael Snee

Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Sue Cheeseman

REAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Majid Riaz

REAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Will Sopwith

REAL Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Carlos Chaib

Research & Development Medical Affairs, Bristol Myers Squibb, Madrid, Spain

John R Penrod

Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA

Melinda J Daumont

Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Braine-l’Alleud, Belgium